Sulfonylurea News and Research

RSS
Phase III clinical trials: Linagliptin achieves significant, sustained reductions in blood sugar

Phase III clinical trials: Linagliptin achieves significant, sustained reductions in blood sugar

Data shows Victoza produces greater reductions in A1c, body weight and FPG than Januvia

Data shows Victoza produces greater reductions in A1c, body weight and FPG than Januvia

Data on BYETTA and SYMLIN injections, BYDUREON drug candidate to be presented at ADA 2010

Data on BYETTA and SYMLIN injections, BYDUREON drug candidate to be presented at ADA 2010

DURATION-4 study tests superiority of BYDUREON as compared to other type 2 diabetes medications

DURATION-4 study tests superiority of BYDUREON as compared to other type 2 diabetes medications

Health Canada approves Victoza for treatment of adults with type 2 diabetes

Health Canada approves Victoza for treatment of adults with type 2 diabetes

FDA assigns BYDUREON new PDUFA action date of October 22, 2010

FDA assigns BYDUREON new PDUFA action date of October 22, 2010

Takeda settles with six defendants in generic ACTOS, ACTOplus met patent infringement lawsuit

Takeda settles with six defendants in generic ACTOS, ACTOplus met patent infringement lawsuit

Victoza produces greater reductions in A1C, FPG and body weight than Januvia: Study

Victoza produces greater reductions in A1C, FPG and body weight than Januvia: Study

Amylin, Eli Lilly and Alkermes reply to FDA complete response letter for BYDUREON NDA

Amylin, Eli Lilly and Alkermes reply to FDA complete response letter for BYDUREON NDA

Positive top-line results from Phenomix' Phase 3 trial of dutogliptin for Type 2 diabetes mellitus

Positive top-line results from Phenomix' Phase 3 trial of dutogliptin for Type 2 diabetes mellitus

Patients switching to Victoza experience further reductions in A1c and weight loss

Patients switching to Victoza experience further reductions in A1c and weight loss

NDA for BYDUREON: FDA issues complete response letter

NDA for BYDUREON: FDA issues complete response letter

Isis Pharmaceuticals reports revenues of $32.3M for fourth-quarter 2009

Isis Pharmaceuticals reports revenues of $32.3M for fourth-quarter 2009

Ipsen’s 2009 performance: Azzalure, Dysport and Decapeptyl approval, Adenuric partnership, drug sales up 7.6%

Ipsen’s 2009 performance: Azzalure, Dysport and Decapeptyl approval, Adenuric partnership, drug sales up 7.6%

GlaxoSmithKline responds to Staff Report on GlaxoSmithKline and the Diabetes Drug Avandia

GlaxoSmithKline responds to Staff Report on GlaxoSmithKline and the Diabetes Drug Avandia

Ipsen reports consolidated group sales of €1,032.8M for 2009

Ipsen reports consolidated group sales of €1,032.8M for 2009

Diabetes journal reviews the role of hypoglycemia in criminal behavior

Diabetes journal reviews the role of hypoglycemia in criminal behavior

FDA approves Novo Nordisk's Victoza for type 2 diabetes

FDA approves Novo Nordisk's Victoza for type 2 diabetes

Roche discloses results of two of eight taspoglutide T-emerge phase III studies in diabetes patients

Roche discloses results of two of eight taspoglutide T-emerge phase III studies in diabetes patients

Positive results from study comparing exenatide once weekly to BYETTA

Positive results from study comparing exenatide once weekly to BYETTA